Protocol Ledger

NCT05811442 · Phase II · COMPLETED

Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

Interventional Phase II clinical trial protocol NCT05811442 sponsored by Beijing Joekai Biotechnology in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-18 Enrollment: 68 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05811442
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)68 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05811442
Protocol FieldVerified Registry Value
NCT IdentifierNCT05811442
Consolidated Lead SponsorBeijing Joekai Biotechnology
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment68 participants (ACTUAL)
Registered Start Date2023-04-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI